Skip to content

Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail

Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03205098
Acronym
ISKETRAIL
Enrollment
200
Registered
2017-07-02
Start date
2015-06-19
Completion date
2016-09-30
Last updated
2017-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ultra-trail Participation

Keywords

biological markers, mesenteric ischemia, ultratrail

Brief summary

To assess the evolution of biological markers of mesenteric ischemia during ultratrail.

Detailed description

During physical exercise, increased sympathetic nervous system activity redistributes blood flow from splanchnic organs to working muscles. With prolonged duration and / or intensity, the splanchnic blood flow can be reduced by 80% or more. A severely reduced of splanchnic blood flow can frequently cause gastrointestinal ischemia. This ischemia associated with reduced vagal activity probably results in changes in motility and absorption. High symptoms are reported in 40% of runners with reflux and heartburn in 15-20% of runners. The low symptoms have an incidence of about 70% in the long runs type ultra-trail. Biological markers such as I-FABP have been shown to be useful in the diagnosis of mesenteric ischemia.

Interventions

BIOLOGICALBlood analysis

Blood test of biological markers of mesenteric ischemia

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy Voluntary Subject * Age \> 18 years * Written consent * Subject affiliated to Social Security * Medical certificate (mandatory to take part in the ultra-trail)

Exclusion criteria

* Refusal to participate * Subject with legal protection (guardianship, trusteeship)

Design outcomes

Primary

MeasureTime frameDescription
Assess biological markers of mesenteric ischemia (IFABP)at day 1during ultratrail.

Secondary

MeasureTime frame
Relationship between digestive symptoms and biological markers (IFABP).at day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026